HCG Tests in the Management of Gestational Trophoblastic Diseases

Cole, Laurence A.; Sutton, Jaime M.

doi:10.1097/00003081-200309000-00005

Cited by 33 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ANC and HCG/β-HCG levels are the sensitive and representative indexes for predicting main toxicities and efficacy; most important, they can be quantitatively evaluated and are superior to other clinical indexes. [23][24][25] Furthermore, after comparing the clinical efficacy and toxicities between 5-FU and FUDR treatments in GTT patients, no obvious differences were found, which is consistent with the in vitro results. 40 Chemotherapeutic efficacy is normally associated with dose intensity, which is defined as the amount of drug delivered per unit of time, regardless of the schedule used.…”

Section: Discussionsupporting

confidence: 78%

Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics

Jiang¹,

Lu²,

Jiang³

et al. 2004

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Dihydropyrimidine dehydrogenase (DPD) deficiency in patients causes severe toxicities in 5-fluorouracil/floxuridine (5-FU/FUDR) treatments. To determine the plasma dihydrouracil/uracil ratio (DUUR) as a potential index for setting 5-FU/FUDR doses, the authors conducted a prospective study on the relationships of the DUUR with 5-FU/FUDR pharmacokinetic and pharmacodynamic parameters. Forty gestational trophoblastic tumor (GTT) patients were treated with 30 mg/kg of 5-FU or prodrug FUDR during a 10-day cycle. The pretreatment DUURs of the patients were determined prior to the treatments, and plasma 5-FU and FUDR concentrations on day 1 of the test cycle were measured to calculate the corresponding pharmacokinetic parameters. The absolute neutrophil count (ANC) and human chorionic gonadotrophins (HCG/beta-HCG) were recorded as the efficacy indexes. The correlation of the DUUR with pharmacokinetic parameters and efficacy indexes was analyzed to look for a relationship between individual doses (in milligrams) and the varied DUUR. Pretreatment DUUR was significantly correlated with the corresponding plasma AUC (r > 0.80, P < .01), the plasma drug clearance (r > 0.78, P < .01), the ANC (r > 0.76, P < 0.01), and the decrease of HCG/beta-HCG levels (r > 0.5, P < 0.01). In addition, the charts for setting 5-FU/FUDR doses were designed for further validation in clinical trials. These findings indicate the important roles of the DUUR in remarkable interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics and propose a better index for setting individual 5-FU/FUDR doses based on interpatient variations in DPD levels.

show abstract

Section: Discussionsupporting

confidence: 78%

Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics

Jiang¹,

Lu²,

Jiang³

et al. 2004

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In view of the heterogeneity of hCG (i.e., apart from the regular a and b-subunits, hCG also occurred in different forms like hyperglycosylated hCG, nicked hCG, hCG without b-subunit C terminal peptide, free b-subunit, nicked free b-subunit), the use of monoclonal antibody in hCG assay is questionable and is regarded as one of the main factors responsible for the variations in hCG measurement. [17,18] Because hCG exists in serum or urine in various forms and is unable to recognize all the forms by the particular clone of monoclonal antibody used in the said immunoassay, which causes variation in hCG results. [19] To minimize these variations, generally, in the commercial kits, a mixture of monoclonal antibodies directed against different hCG epitopes are used.…”

Section: Discussionmentioning

confidence: 99%

Development of Isotopic and Non‐Isotopic Microwell Based Immunoassays for hCG Using¹²⁵I and Biotin Labeled hCG

Basu

Shrivastav

Maitra

2005

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

Isotopic and non-isotopic immunoassays of hCG, based on the principle of competitive inhibition, using micro-well as solid support and 125I and biotin as labels for hCG, have been developed. In both the assays, rabbit polyclonal antibody was immobilized onto micro-wells. In the non-isotopic assay, to the hCG antibody coated micro-wells, 50 microL of standard or samples along with 100 microL of biotinylated hCG were incubated for 1 hour at 37 degrees C. After incubation, wells were washed and 100 microL of streptavidin-HRP conjugate was added to each well and incubated again for a half hour at 37 degrees C. Bound enzyme activity was measured using tertramethyl benzidine/hydrogen peroxide (TMB/H2O2) as substrate. In the isotopic assay, to the hCG antibody coated micro-wells, 50 microL of standard or samples along with 100 microL of 125I-hCG were incubated for 1 hour at 37 degrees C. The bound radioactivity was measured using a gamma counter. The sensitivities of the non-isotopic and isotopic assays were 0.12 IU/mL and 0.1 IU/mL, respectively. The intra- and inter-assay CVs for both the assays were less than 12.3%. There was a good correlation between the developed non-isotopic and isotopic immunoassays (r = 0.97, n = 20).

show abstract

“…It has been found to be higher in serum and urine of individuals with pre-eclampsia, trophoblast disease, Down syndrome and male or female patients with testicular or bladder cancer. It is, still, the principal molecular form of hCG found in the weeks following molar evacuation or chemotherapy for hydatiform mole or choriocarcinoma (Cole and Sutton, 2003).…”

Section: Nicked Human Chorionic Gonadotrophinmentioning

confidence: 99%

Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights

Yamamoto

Norman

2008

Human Reproduction Update

View full text Add to dashboard Cite

show abstract

HCG Tests in the Management of Gestational Trophoblastic Diseases

Cited by 33 publications

References 15 publications

Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics

Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics

Development of Isotopic and Non‐Isotopic Microwell Based Immunoassays for hCG Using¹²⁵I and Biotin Labeled hCG

Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights

Contact Info

Product

Resources

About

HCG Tests in the Management of Gestational Trophoblastic Diseases

Cited by 33 publications

References 15 publications

Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics

Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics

Development of Isotopic and Non‐Isotopic Microwell Based Immunoassays for hCG Using125I and Biotin Labeled hCG

Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights

Contact Info

Product

Resources

About

Development of Isotopic and Non‐Isotopic Microwell Based Immunoassays for hCG Using¹²⁵I and Biotin Labeled hCG